Cytek Biosciences (CTKB) Total Non-Current Liabilities (2020 - 2026)

Cytek Biosciences (CTKB) has 7 years of Total Non-Current Liabilities data on file, last reported at $119.1 million in Q1 2026.

• Quarterly Total Non-Current Liabilities rose 26.46% year-over-year to $119.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $119.1 million (up 26.46% YoY) and the FY2025 annual result came in at $117.5 million, up 15.87% from the prior year.
• Total Non-Current Liabilities rose to $119.1 million in Q1 2026, from $117.5 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $119.1 million in Q1 2026 to a low of $67.7 million in Q3 2022.
• A 5-year average of $96.1 million and a median of $99.0 million in 2023 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2022 — Total Non-Current Liabilities surged 75.79% — and 2024, when it dropped 7.96%.
• Tracing CTKB's Total Non-Current Liabilities over 5 years: stood at $92.3 million in 2022, then increased by 7.17% to $99.0 million in 2023, then gained by 2.46% to $101.4 million in 2024, then grew by 15.87% to $117.5 million in 2025, then climbed by 1.34% to $119.1 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $119.1 million (Q1 2026), $117.5 million (Q4 2025), and $113.8 million (Q3 2025), per Business Quant data.